en
Scientific article
English

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

Published inFuture oncology, vol. 12, no. 6, p. 739-749
Publication date2016
Abstract

Current treatments for polycythemia vera have remained unchanged for decades with phlebotomy, hydroxycarbamide (also named hydroxyurea) and to a lesser extent interferon being the cornerstones in our therapeutic armamentarium. However, some patients do not respond to, or indeed experience significant side effects to, these current agents and development of alternative therapeutic options is required. Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide. In this article, we review the currently available efficacy and safety data.

Keywords
  • Myeloproliferative neoplasms
  • Outcomes
  • Polycythemia vera
  • Ruxolitinib
  • Treatment
Affiliation Not a UNIGE publication
Citation (ISO format)
BEAUVERD, Yan et al. Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera? In: Future oncology, 2016, vol. 12, n° 6, p. 739–749. doi: 10.2217/fon-2015-0023
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1479-6694
480views
3downloads

Technical informations

Creation03/04/2016 1:11:00 PM
First validation03/04/2016 1:11:00 PM
Update time03/15/2023 12:23:05 AM
Status update03/15/2023 12:23:05 AM
Last indexation01/16/2024 8:52:53 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack